NCT04511130Phase 2Terminated

Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Study sponsor: Marker Therapeutics, Inc. · MRKR

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-03-01Actual
Enrollment · participants92Actual
Source updated2025-10-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview